Kura Oncology (NASDAQ:KURA) Price Target Raised to $40.00 at HC Wainwright

Kura Oncology (NASDAQ:KURA) had its price objective upped by HC Wainwright from $37.00 to $40.00 in a research report released on Thursday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other research firms have also recently issued reports on KURA. Scotiabank lowered their target price on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research note on Wednesday, January 8th. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research report on Monday, December 9th. UBS Group initiated coverage on shares of Kura Oncology in a research report on Thursday, October 24th. They issued a “buy” rating and a $27.00 price objective on the stock. JMP Securities reiterated a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a report on Tuesday, November 19th. Finally, StockNews.com downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $27.13.

Kura Oncology Price Performance

KURA opened at $8.82 on Thursday. Kura Oncology has a twelve month low of $6.98 and a twelve month high of $24.17. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The firm’s fifty day moving average is $8.79 and its two-hundred day moving average is $15.11.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.01. During the same period in the prior year, the company earned ($0.50) earnings per share. Equities research analysts forecast that Kura Oncology will post -2.44 earnings per share for the current year.

Insider Buying and Selling at Kura Oncology

In related news, SVP Thomas James Doyle sold 4,949 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares in the company, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now owns 88,253 shares of the company’s stock, valued at $694,551.11. The trade was a 5.32 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 12,255 shares of company stock worth $100,739 over the last ninety days. 5.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. nVerses Capital LLC bought a new position in Kura Oncology during the third quarter worth $25,000. Point72 DIFC Ltd acquired a new position in Kura Oncology in the 3rd quarter valued at about $146,000. E Fund Management Co. Ltd. acquired a new stake in Kura Oncology during the fourth quarter worth approximately $90,000. Erste Asset Management GmbH acquired a new position in shares of Kura Oncology in the third quarter valued at approximately $215,000. Finally, Bellevue Group AG increased its stake in shares of Kura Oncology by 36.0% during the third quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock worth $266,000 after purchasing an additional 3,600 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.